Incidence of platelet alloimmunization
. | Pre-ULR group*(%) . | Post-ULR group*(%) . | P . |
|---|---|---|---|
| Overall | 61/315 (19) | 21/302 (7) | < .001§ |
| Chemotherapy or supportive care | 26/116 (22) | 11/117 (9) | .011§ |
| ALL | 2/20 (10) | 1/11 (9) | .99∥ |
| AML | 19/84 (23) | 10/97 (10) | .027∥ |
| Supportive care | 5/12 (42) | 0/9 (0) | .045∥ |
| SCT | 35/199 (18) | 10/185 (5) | .004∥ |
| ALLO RD | 10/75 (13) | 3/72 (4) | .050§ |
| ALLO VUD | 11/39 (28) | 6/32 (19) | .35§ |
| AUTO BM | 7/39 (18) | 1/24 (4) | .14∥ |
| AUTO PB | 7/46 (15) | 0/57 (0) | .003∥ |
| Nulliparous/nontransfused† | 16/144 (11) | 6/152 (4) | .026§ |
| Parous/transfused‡ | 39/154 (25) | 15/139 (11) | .023§ |
| Parous only | 7/46 (15) | 6/59 (10) | .44∥ |
| Transfused only | 22/75 (29) | 1/53 (2) | < .001∥ |
| Both | 6/26 (23) | 7/25 (28) | .75∥ |
. | Pre-ULR group*(%) . | Post-ULR group*(%) . | P . |
|---|---|---|---|
| Overall | 61/315 (19) | 21/302 (7) | < .001§ |
| Chemotherapy or supportive care | 26/116 (22) | 11/117 (9) | .011§ |
| ALL | 2/20 (10) | 1/11 (9) | .99∥ |
| AML | 19/84 (23) | 10/97 (10) | .027∥ |
| Supportive care | 5/12 (42) | 0/9 (0) | .045∥ |
| SCT | 35/199 (18) | 10/185 (5) | .004∥ |
| ALLO RD | 10/75 (13) | 3/72 (4) | .050§ |
| ALLO VUD | 11/39 (28) | 6/32 (19) | .35§ |
| AUTO BM | 7/39 (18) | 1/24 (4) | .14∥ |
| AUTO PB | 7/46 (15) | 0/57 (0) | .003∥ |
| Nulliparous/nontransfused† | 16/144 (11) | 6/152 (4) | .026§ |
| Parous/transfused‡ | 39/154 (25) | 15/139 (11) | .023§ |
| Parous only | 7/46 (15) | 6/59 (10) | .44∥ |
| Transfused only | 22/75 (29) | 1/53 (2) | < .001∥ |
| Both | 6/26 (23) | 7/25 (28) | .75∥ |
Abbreviations are explained in Table 2.
Number of patients with positive lymphocytotoxic antibody screen on 2 or more consecutive occasions/total number of patients in the group.
No history of pregnancy and/or blood transfusion.
History of pregnancy and/or blood transfusion. The parity of 9 transfused patients could not be determined.
Chi-square test.
Fisher exact test.